A Phase 2 Trial of ALIMTA (Pemetrexed) Plus Gemcitabine in Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

Definition: Patients with bladder cancer will be participating in this study for the treatment of abnormal cells in the bladder that have returned after initial treatment OR have moved to a new site in the body.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Eli Lilly and Company
• Treatments: Gemcitabine; Pemetrexed

Criteria

Inclusion Criteria:

• You must have been diagnosed with bladder cancer that has recurred or moved to a new part of the body.

• You must have at least one tumor that can be physically measured or scanned by x-ray.

• You may not have had previous chemotherapy (drug) treatment OR you have had surgery followed by one chemotherapy treatment at least 4 months ago.

Exclusion Criteria:

• You may not have used an experimental medicine or device within the past month.

• Cancer that has spread to your brain.

• If you are unwilling or unable to take folic acid or vitamin B12 supplements.